KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Assets Average: 2009-2025

Historic Assets Average for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $7.5 billion.

  • Charles River Laboratories International's Assets Average fell 5.50% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 billion, marking a year-over-year decrease of 5.50%. This contributed to the annual value of $7.9 billion for FY2024, which is 0.47% down from last year.
  • Per Charles River Laboratories International's latest filing, its Assets Average stood at $7.5 billion for Q3 2025, which was down 0.45% from $7.6 billion recorded in Q2 2025.
  • Charles River Laboratories International's 5-year Assets Average high stood at $8.2 billion for Q1 2024, and its period low was $5.6 billion during Q1 2021.
  • In the last 3 years, Charles River Laboratories International's Assets Average had a median value of $7.7 billion in 2023 and averaged $7.8 billion.
  • As far as peak fluctuations go, Charles River Laboratories International's Assets Average soared by 31.80% in 2021, and later declined by 7.57% in 2025.
  • Quarterly analysis of 5 years shows Charles River Laboratories International's Assets Average stood at $7.0 billion in 2021, then climbed by 6.41% to $7.5 billion in 2022, then grew by 5.45% to $7.9 billion in 2023, then dropped by 1.71% to $7.8 billion in 2024, then fell by 5.50% to $7.5 billion in 2025.
  • Its Assets Average was $7.5 billion in Q3 2025, compared to $7.6 billion in Q2 2025 and $7.6 billion in Q1 2025.